Celadon Pharmaceuticals (LSE:CEL) Additional Paid-In Capital : £27.12 Mil(As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Additional Paid-In Capital?

Celadon Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2023 (£22.60 Mil) to Dec. 2023 (£25.55 Mil) and increased from Dec. 2023 (£25.55 Mil) to Jun. 2024 (£27.12 Mil).

Celadon Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (£0.00 Mil) to Dec. 2022 (£22.60 Mil) and increased from Dec. 2022 (£22.60 Mil) to Dec. 2023 (£25.55 Mil).

Celadon Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Celadon Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Additional Paid-In Capital Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.27

22.60

25.55

Celadon Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial					22.60	22.60	22.60	25.55	27.12

Celadon Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Celadon Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis. It operates only in the UK and has only one geographical area.

Celadon Pharmaceuticals Headlines

No Headlines